A Clinical Study of AK139 in Healthy Subjects
A Phase I Clinical Study on Dose Escalation Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of AK139 in Healthy Subjects.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Guoqin Wang
- Phone Number: 86 (0760) 8987 3999
- Email: global.trials@akesobio.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Zhejiang Xiaoshan Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects voluntarily agree to participate and sign an informed consent form (ICF) before any study procedures begin.
- Male and female healthy subjects aged 18 to 55 at the time of signing the ICF.
- Male weight ≥ 50.0kg, female weight ≥ 45.0kg; Body Mass Index (BMI)=Weight (kg)/Height² (m²), within the range of 19.0~26.0 kg/m².
- Female subjects with fertility tested negative for pregnancy during the screening period.
- The subjects are able to communicate well with the investigator and understand and comply with the requirements of this study.
Exclusion Criteria:
- Allergies to AK139 components and any monoclonal antibodies.
- Positive results of confirmatory serology test for hepatitis B, hepatitis C,HIV or syphilis at screening.
- have participated in any drug clinical study within 3 months prior to randomization, or are still within 5 half-lives after the last administration of other investigational drugs (whichever is longer)
- Previously or currently suffering from any diseases of the circulatory, endocrine, neurological, digestive, respiratory, urogenital, blood, immune, psychiatric, or metabolic systems that may interfere with the test results.
- History of parasitic infection.
- Drug abusers or individuals with positive urine drug results during screening.
- Have donated blood or experienced significant blood loss, received blood transfusions, or used blood products 3 months before screening.
- Investigator assessed that it is not suitable to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Monitor for a minimum of 24 hours to assess whether the safety and tolerability are acceptable according to the investigator.
|
|
Active Comparator: AK139 regimen
|
The study will use dose escalation scheme.
Before proceeding to randomize the next group of subjects, the safety data from all subjects in the previous dose group must be reviewed and confirmed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events (AE)
Time Frame: Baseline to week 12
|
The incidence of AEs .
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
|
Baseline to week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak concentration (Cmax)
Time Frame: Week 0 to week 12
|
Measure and assess the Cmax of AK139.
|
Week 0 to week 12
|
|
Time to peak (Tmax)
Time Frame: Week 0 to week 12
|
Measure and assess the Tmax of AK139
|
Week 0 to week 12
|
|
Area under the curve (AUC)
Time Frame: Week 0 to week 12
|
Measure and assess the AUC of AK139
|
Week 0 to week 12
|
|
Half-life (t1/2)
Time Frame: Week 0 to week 12
|
Measure and assess the t1/2 of AK139.
|
Week 0 to week 12
|
|
Anti-drug antibody (ADA)
Time Frame: Week 0/2/4/8/12
|
Measure and assess the ADA of AK139.
|
Week 0/2/4/8/12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- AK139-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.